Plasminogen activator inhibitor-1 antagonist TM5441 attenuates Nω-Nitro-L-Arginine methyl ester-induced hypertension and vascular senescence

Circulation

Volumn 128, Issue 21, 2013, Pages 2318-2324

  Boe, Amanda E ^a   Eren, Mesut ^a   Murphy, Sheila B ^a   Kamide, Christine E ^a   Ichimura, Atsuhiko ^b   Terry, David ^c   McAnally, Danielle ^c   Smith, Layton H ^c   Miyata, Toshio ^b   Vaughan, Douglas E ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c BURNHAM INSTITUTE   (United States)

Author keywords

Aging; Hypertension; Nitric oxide synthase

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; N(G) NITROARGININE METHYL ESTER; PLASMINOGEN ACTIVATOR; TM 5441; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHROMOSOMAL PARAMETERS; CHROMOSOME STRUCTURE; CONTROLLED STUDY; DRUG BLOOD LEVEL; HEART VENTRICLE HYPERTROPHY; HYPERTENSION; LIQUID CHROMATOGRAPHY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; SENESCENCE; STRUCTURE ACTIVITY RELATION; SYSTOLIC BLOOD PRESSURE; TANDEM MASS SPECTROMETRY; TELOMERE; TELOMERE LENGTH; VASCULAR FIBROSIS; VASCULAR SENESCENCE; WILD TYPE;

AGING; HYPERTENSION; NITRIC OXIDE SYNTHASE;

ANIMALS; AORTA; BLOOD PRESSURE; CARDIOMEGALY; CELL AGING; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; HYPERTENSION; MALE; MICE; MICE, INBRED C57BL; NG-NITROARGININE METHYL ESTER; PARA-AMINOBENZOATES; PIPERAZINES; RATS; RATS, WISTAR; SERPIN E2; STRUCTURE-ACTIVITY RELATIONSHIP; TELOMERE;

EID: 84888206541     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.113.003192     Document Type: Article

References (38)

1. Knowles RG, Moncada S. Nitric oxide synthases in mammals. Biochem J. 1994;298 (Pt 2):249-258.
2. Félétou M, Köhler R, Vanhoutte PM. Nitric oxide: Orchestrator of endothelium-dependent responses. Ann Med. 2012;44:694-716.
3. Huang PL, Huang Z, Mashimo H, Bloch KD, Moskowitz MA, Bevan JA, Fishman MC. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature. 1995;377:239-242.
4. Shesely EG, Maeda N, Kim HS, Desai KM, Krege JH, Laubach VE, Sherman PA, Sessa WC, Smithies O. Elevated blood pressures in mice lacking endothelial nitric oxide synthase. Proc Natl Acad Sci USA. 1996;93:13176-13181.
5. Zatz R, Baylis C. Chronic nitric oxide inhibition model six years on. Hypertension. 1998;32:958-964.
6. Baylis C, Mitruka B, Deng A. Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Invest. 1992;90:278-281.
7. Ribeiro MO, Antunes E, de Nucci G, Lovisolo SM, Zatz R. Chronic inhibition of nitric oxide synthesis. A new model of arterial hypertension. Hypertension. 1992;20:298-303.
8. Bouchie JL, Hansen H, Feener EP. Natriuretic factors and nitric oxide suppress plasminogen activator inhibitor-1 expression in vascular smooth muscle cells. Role of cGMP in the regulation of the plasminogen system. Arterioscler Thromb Vasc Biol. 1998;18:1771-1779.
9. Katoh M, Egashira K, Mitsui T, Chishima S, Takeshita A, Narita H. Angiotensin-converting enzyme inhibitor prevents plasminogen activator inhibitor-1 expression in a rat model with cardiovascular remodeling induced by chronic inhibition of nitric oxide synthesis. J Mol Cell Cardiol. 2000;32:73-83.
10. Vaughan DE. Plasminogen Activator Inhibitor 1: Molecular Aspects and Clinical Importance. J Thromb Thrombolysis. 1995;2:187-193.
11. Stefansson S, Lawrence DA. The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin. Nature. 1996;383:441-443.
12. Heymans S, Luttun A, Nuyens D, Theilmeier G, Creemers E, Moons L, Dyspersin GD, Cleutjens JP, Shipley M, Angellilo A, Levi M, Nübe O, Baker A, Keshet E, Lupu F, Herbert JM, Smits JF, Shapiro SD, Baes M, Borgers M, Collen D, Daemen MJ, Carmeliet P. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med. 1999;5:1135-1142.
13. Olman MA, Mackman N, Gladson CL, Moser KM, Loskutoff DJ. Changes in procoagulant and fibrinolytic gene expression during bleomycin-induced lung injury in the mouse. J Clin Invest. 1995;96:1621-1630.
14. Oikawa T, Freeman M, Lo W, Vaughan DE, Fogo A. Modulation of plasminogen activator inhibitor-1 in vivo: A new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition. Kidney Int. 1997;51:164-172.
15. Eren M, Painter CA, Atkinson JB, Declerck PJ, Vaughan DE. Agedependent spontaneous coronary arterial thrombosis in transgenic mice that express a stable form of human plasminogen activator inhibitor-1. Circulation. 2002;106:491-496.
16. Kaikita K, Fogo AB, Ma L, Schoenhard JA, Brown NJ, Vaughan DE. Plasminogen activator inhibitor-1 deficiency prevents hypertension and vascular fibrosis in response to long-term nitric oxide synthase inhibition. Circulation. 2001;104:839-844.
17. Kaikita K, Schoenhard JA, Painter CA, Ripley RT, Brown NJ, Fogo AB, Vaughan DE. Potential roles of plasminogen activator system in coronary vascular remodeling induced by long-term nitric oxide synthase inhibition. J Mol Cell Cardiol. 2002;34:617-627.
18. Izuhara Y, Yamaoka N, Kodama H, Dan T, Takizawa S, Hirayama N, Meguro K, van Ypersele de Strihou C, Miyata T. A novel inhibitor of plasminogen activator inhibitor-1 provides antithrombotic benefits devoid of bleeding effect in nonhuman primates. J Cereb Blood Flow Metab. 2010;30:904-912.
19. Izuhara Y, Takahashi S, Nangaku M, Takizawa S, Ishida H, Kurokawa K, van Ypersele de Strihou C, Hirayama N, Miyata T. Inhibition of plasminogen activator inhibitor-1: Its mechanism and effectiveness on coagulation and fibrosis. Arterioscler Thromb Vasc Biol. 2008;28:672-677.
20. Sato I, Morita I, Kaji K, Ikeda M, Nagao M, Murota S. Reduction of nitric oxide producing activity associated with in vitro aging in cultured human umbilical vein endothelial cell. Biochem Biophys Res Commun. 1993;195:1070-1076.
21. Matsushita H, Chang E, Glassford AJ, Cooke JP, Chiu CP, Tsao PS. eNOS activity is reduced in senescent human endothelial cells: Preservation by hTERT immortalization. Circ Res. 2001;89:793-798.
22. Hayashi T, Matsui-Hirai H, Miyazaki-Akita A, Fukatsu A, Funami J, Ding QF, Kamalanathan S, Hattori Y, Ignarro LJ, Iguchi A. Endothelial cellular senescence is inhibited by nitric oxide: Implications in atherosclerosis associated with menopause and diabetes. Proc Natl Acad Sci USA. 2006;103:17018-17023.
23. Zhong W, Zou G, Gu J, Zhang J. L-arginine attenuates high glucose-accelerated senescence in human umbilical vein endothelial cells. Diabetes Res Clin Pract. 2010;89:38-45.
24. Kuilman T, Peeper DS. Senescence-messaging secretome: SMS-ing cellular stress. Nat Rev Cancer. 2009;9:81-94.
25. Kortlever RM, Higgins PJ, Bernards R. Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nat Cell Biol. 2006;8:877-884.
26. Elzi DJ, Lai Y, Song M, Hakala K, Weintraub ST, Shiio Y. Plasminogen activator inhibitor 1-insulin-like growth factor binding protein 3 cascade regulates stress-induced senescence. Proc Natl Acad Sci USA. 2012;109:12052-12057.
27. Izuhara Y, Takahashi S, Nangaku M, Takizawa S, Ishida H, Kurokawa K, van Ypersele de Strihou C, Hirayama N, Miyata T. Inhibition of plasminogen activator inhibitor-1: Its mechanism and effectiveness on coagulation and fibrosis. Arterioscler Thromb Vasc Biol. 2008;28:672-677.
28. Izuhara Y, Yamaoka N, Kodama H, Dan T, Takizawa S, Hirayama N, Meguro K, van Ypersele de Strihou C, Miyata T. A novel inhibitor of plasminogen activator inhibitor-1 provides antithrombotic benefits devoid of bleeding effect in nonhuman primates. J Cereb Blood Flow Metab. 2010;30:904-912.
29. Cawthon RM. Telomere measurement by quantitative PCR. Nucleic Acids Res. 2002;30:e47.
30. Callicott RJ, Womack JE. Real-time PCR assay for measurement of mouse telomeres. Comp Med. 2006;56:17-22.
31. Eitzman DT, McCoy RD, Zheng X, Fay WP, Shen T, Ginsburg D, Simon RH. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest. 1996;97:232-237.
32. Eren M, Gleaves LA, Atkinson JB, King LE, Declerck PJ, Vaughan DE. Reactive site-dependent phenotypic alterations in plasminogen activator inhibitor-1 transgenic mice. J Thromb Haemost. 2007;5:1500-1508.
33. Weisberg AD, Albornoz F, Griffin JP, Crandall DL, Elokdah H, Fogo AB, Vaughan DE, Brown NJ. Pharmacological inhibition and genetic deficiency of plasminogen activator inhibitor-1 attenuates angiotensin II/salt-induced aortic remodeling. Arterioscler Thromb Vasc Biol. 2005;25:365-371.
34. Smith LH, Dixon JD, Stringham JR, Eren M, Elokdah H, Crandall DL, Washington K, Vaughan DE. Pivotal role of PAI-1 in a murine model of hepatic vein thrombosis. Blood. 2006;107:132-134.
35. Najjar SS, Scuteri A, Lakatta EG. Arterial aging: Is it an immutable cardiovascular risk factor? Hypertension. 2005;46:454-462.
36. Jousilahti P, Vartiainen E, Tuomilehto J, Puska P. Sex, age, cardiovascular risk factors, and coronary heart disease: A prospective follow-up study of 14 786 middle-aged men and women in Finland. Circulation. 1999;99:1165-1172.
37. Yamamoto K, Takeshita K, Kojima T, Takamatsu J, Saito H. Aging and plasminogen activator inhibitor-1 (PAI-1) regulation: Implication in the pathogenesis of thrombotic disorders in the elderly. Cardiovasc Res. 2005;66:276-285.
38. Lyons D, Roy S, Patel M, Benjamin N, Swift CG. Impaired nitric oxidemediated vasodilatation and total body nitric oxide production in healthy old age. Clin Sci. 1997;93:519-525.